



FORM PTO-1449 (Modified) Approved for use through 10/31/2002 INFORMATION DISCLOSURE CITATION in an Application (Use several sheets if necessary)	US DEPARTMENT OF COMMERCE US Patent and Trademark Office	Docket No. 50623.370	Application No. 10/772,858
	Applicant Syed F.A. Hossainy		
	Filing Date February 4, 2004	Group Art Unit 4734 1762	

U.S. PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
ECC	A1	3,288,052	11/29/66	Hough	99	235	
	A2	4,148,932	4/10/79	Tada et al.	427	31	
	A3	4,275,838	6/30/81	Fangmeyer	239	223	
	A4	4,329,383	5/11/82	Joh	428	36	
	A5	4,589,597	5/20/86	Robisch et al.	239	703	
	A6	4,684,064	8/4/87	Kwok	239	223	
	A7	4,733,665	3/29/88	Palmaz	128	343	
	A8	4,795,095	1/3/89	Shepard	239	214.17	
	A9	4,800,882	1/31/89	Gianturco	128	343	
	A10	4,882,168	11/21/89	Casey et al.	424	468	
	A11	4,886,062	12/12/89	Wiktor	128	343	
	A12	4,927,081	5/22/90	Kwok et al.	239	223	
	A13	4,941,870	7/17/90	Okada et al.	600	36	
	A14	4,977,901	12/18/90	Ofstead	128	772	
	A15	5,112,457	5/12/92	Marchant	204	165	
	A16	5,165,919	11/24/92	Sasaki et al.	424	488	
	A17	5,272,012	12/21/93	Opolski	428	423.1	
	A18	5,292,516	3/8/94	Viegas et al.	424	423	
	A19	5,298,260	3/29/94	Viegas et al.	424	486	
	A20	5,300,295	4/5/94	Viegas et al.	424	427	
	A21	5,306,501	4/26/94	Viegas et al.	424	423	
	A22	5,328,471	7/12/94	Slepian	604	101	
	A23	5,330,768	7/19/94	Park et al.	424	501	
	A24	5,380,299	1/10/95	Fearnot et al.	604	265	
	A25	5,399,198	3/21/95	Ghaisas	118	629	
ECC	A26	5,417,981	5/23/95	Endo et al.	424	486	

Ecc	A27	5,447,724	9/5/95	Helmus et al.	424	426	
	A28	5,455,040	10/3/95	Marchant	424	426	
	A29	5,462,990	10/31/95	Hubbell et al.	525	54.1	
	A30	5,464,650	11/7/95	Berg et al.	427	2.30	
	A31	5,569,463	10/29/96	Helmus et al.	424	426	
	A32	5,578,073	11/26/96	Haimovich et al.	623	1	
	A33	5,605,696	2/25/97	Eury et al.	424	423	
	A34	5,609,629	3/11/97	Fearnot et al.	623	1	
	A35	5,624,411	4/29/97	Tuch	604	265	
	A36	5,628,730	5/13/97	Shapland et al.	604	21	
	A37	5,649,977	7/22/97	Campbell	623	1	
	A38	5,658,995	8/19/97	Kohn et al.	525	432	
	A39	5,667,767	9/16/97	Greff et al.	424	9.411	
	A40	5,670,558	9/23/97	Onishi et al.	523	112	
	A41	5,679,400	10/21/97	Tuch	427	2.14	
	A42	5,700,286	12/23/97	Tartaglia et al.	623	1	
	A43	5,702,754	12/30/97	Zhong	427	2.12	
	A44	5,716,981	2/10/98	Hunter et al.	514	449	
	A45	5,735,897	4/7/98	Buirge	623	12	
	A46	5,746,998	5/5/98	Torchilin et al.	424	9.4	
	A47	5,776,184	7/7/98	Tuch	623	1	
	A48	5,788,979	8/4/98	Alt et al.	424	426	
	A49	5,800,392	9/1/98	Racchini	604	96	
	A50	5,820,917	10/13/98	Tuch	427	2.1	
	A51	5,824,048	10/20/98	Tuch	623	1	
	A52	5,824,049	10/20/98	Ragheb et al.	623	1	
	A53	5,830,178	11/3/98	Jones et al.	604	49	
	A54	5,837,008	11/17/98	Berg et al.	623	1	
	A55	5,837,313	11/17/98	Ding et al.	427	2.21	
	A56	5,851,508	12/22/98	Greff et al.	424	9.411	
Ecc	A57	5,858,746	1/12/99	Hubbell et al.	435	177	

ECC	A58	5,865,814	2/2/99	Tuch	604	265	
	A59	5,869,127	2/9/99	Zhong	427	2.12	
	A60	5,873,904	2/23/99	Ragheb et al.	623	1	
	A61	5,876,433	3/2/99	Lunn	623	1	
	A62	5,877,224	3/2/99	Brocchini et al.	514	772.2	
	A63	5,925,720	7/20/99	Kataoka et al.	525	523	
	A64	5,955,509	9/21/99	Webber et al.	514	772.7	
	A65	5,957,974	9/28/99	Thompson et al.	623	1.13	
	A66	5,971,954	10/26/99	Conway et al.	604	96	
	A67	5,980,928	11/9/99	Terry	424	427	
	A68	5,980,972	11/9/99	Ding	427	2.24	
	A69	5,997,517	12/7/99	Whitbourne	604	265	
	A70	6,010,530	1/4/00	Goicoechea	623	1	
	A71	6,015,541	1/18/00	Greff et al.	424	1.25	
	A72	6,033,582	3/7/00	Lee et al.	216	37	
	A73	6,042,875	3/28/00	Ding et al.	427	2.24	
	A74	6,045,864	4/4/00	Lyons et al.	427	255.23	
	A75	6,051,648	4/18/00	Rhee et al.	525	54.1	
	A76	6,051,576	4/18/00	Ashton et al.	514	255	
	A77	6,056,993	5/2/00	Leidner et al.	427	2.25	
	A78	6,060,451	5/9/00	DiMaio et al.	514	13	
	A79	6,060,518	5/9/00	Kabanov et al.	514	781	
	A80	6,080,488	6/27/00	Hostettler et al.	428	423.3	
	A81	6,096,070	8/1/00	Ragheb et al.	623	1	
	A82	6,099,562	8/8/00	Ding et al.	623	1.46	
	A83	6,110,188	8/29/00	Narciso, Jr.	606	153	
	A84	6,110,483	8/29/00	Whitbourne et al.	424	423	
	A85	6,113,629	9/5/00	Ken	623	1.1	
	A86	6,120,536	9/19/00	Ding et al.	623	1.43	
	A87	6,120,904	9/19/00	Hostettler et al.	428	423.3	
	A88	6,121,027	9/19/00	Clapper et al.	435	180	
ECC	A89	6,129,761	10/10/00	Hubbell	623	11	

Ecc	A90	6,153,252	11/28/00	Hossainy et al.	427	2.3	
	A91	6,165,212	12/26/00	Dereume et al.	623	1.13	
	A92	6,189,804	2/20/01	Vetter et al.	239	7	
	A93	6,203,551	3/20/01	Wu	606	108	10/4/99
	A94	6,231,600	5/15/01	Zhong	623	1.42	5/26/99
	A95	6,240,616	6/5/01	Yan	29	527.2	4/15/97
	A96	6,245,753	6/12/01	Byun et al.	514	56	4/27/99
	A97	6,251,136	6/26/01	Guruwaiya et al.	623	1.46	12/8/99
	A98	6,254,632	7/3/01	Wu et al.	623	1.15	9/28/00
	A99	6,258,121	7/10/01	Yang et al.	623	1.46	7/2/99
	A100	6,267,073	7/31/01	Busse et al.	118	24	9/2/98
	A101	6,283,947	9/4/01	Mirzaee	604	264	7/13/99
	A102	6,283,949	9/4/01	Roorda	604	288.02	12/27/99
	A103	6,284,305	9/4/01	Ding et al.	427	2.28	5/18/00
	A104	6,287,628	9/11/01	Hossainy et al.	427	2.3	9/3/99
	A105	6,299,604	10/9/01	Ragheb et al.	604	265	8/20/99
	A106	6,306,176	10/23/01	Whitbourne	623	23.59	9/21/99
	A107	6,331,313	12/18/01	Wong et al.	424	427	10/22/99
	A108	6,335,029	1/1/02	Kamath et al.	424	423	12/3/98
	A109	6,346,110	2/12/02	Wu	606	108	1/3/01
	A110	6,358,556	3/19/02	Ding et al.	427	2.24	1/23/98
	A111	6,379,381	4/30/02	Hossainy et al.	623	1.42	9/3/99
	A112	6,395,326	5/28/02	Castro et al.	427	2.24	5/31/00
	A113	6,419,692	7/16/02	Yang et al.	623	1.15	2/3/99
	A114	6,451,373	9/17/02	Hossainy et al.	427	2.25	8/4/00
	A115	6,494,862	12/17/02	Ray et al.	604	96.01	12/30/99
	A116	6,503,556	1/7/03	Harish et al.	427	2.24	12/28/00
	A117	6,503,954	1/7/03	Bhat et al.	514	772.2	7/21/00
Ecc	A118	6,506,437	1/14/03	Harish et al.	427	2.25	10/17/00

Ecc	A119	6,527,801	3/4/03	Dutta	623	1.46	4/13/00
	A120	6,527,863	3/4/03	Pacetti et al.	118	500	6/29/01
	A121	6,540,776	4/1/03	Sanders Millare et al.	623	1.15	12/28/00
	A122	6,544,223	4/8/03	Kokish	604	103.01	1/5/01
	A123	6,544,543	4/8/03	Mandrusov et al.	424	422	12/27/00
	A124	6,544,582	4/8/03	Yoe	427	2.24	1/5/01
	A125	6,555,157	4/29/03	Hossainy	427	2.24	7/25/00
	A126	6,558,733	5/6/03	Hossainy et al.	427	2.24	10/26/00
	A127	6,565,659	5/20/03	Pacetti et al.	118	500	6/28/01
	A128	6,572,644	6/3/03	Moein	623	1.11	6/27/01
	A129	6,585,765	7/1/03	Hossainy et al.	623	1.45	6/29/00
	A130	6,585,926	7/1/03	Mirzaee	264	400	8/31/00
Ecc	A131	6,605,154	8/12/03	Villareal	118	500	5/31/01

U.S. PATENT APPLICATION PUBLICATION DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	Filing Date If Appropriate
Ecc	A132	2001/0018469	8/30/01	Chen et al.	523	121	12/28/00
Ecc	A133	2001/0037145	11/1/01	Guruwaiya et al.	623	1.15	6/21/01
Ecc	A134	2002/0077693	6/20/02	Barclay et al.	623	1.13	12/19/00
Ecc	A135	2002/0091433	7/11/02	Ding et al.	623	1.2	12/17/01
Ecc	A136	2002/0155212	10/24/02	Hossainy	427	2.25	4/24/01
Ecc	A137	2003/0065377	4/3/03	Davila et al.	623	1.13	4/30/02
Ecc	A138	2003/0099712	5/29/03	Jayaraman	424	486	11/26/01

FOREIGN PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation	
							Yes	No
Ecc	B1	EP 0 301 856	2/1/89	European	—	—		
Ecc	B2	EP 0 514 406	11/25/92	European	—	—		
Ecc	B3	EP 0 604 022	6/29/94	European	—	—		
Ecc	B4	EP 0 623 354	11/9/94	European	—	—		
Ecc	B5	EP 0 665 023	8/2/95	European	—	—		
Ecc	B6	EP 0 701 802	3/20/96	European	—	—		
Ecc	B7	EP 0 716 836	6/19/96	European	—	—		

ECC	B8	EP 0 809 999	12/3/97	European	—	—		
	B9	EP 0 832 655	4/1/98	European	—	—		
	B10	EP 0 850 651	7/1/98	European	—	—		
	B11	EP 0 879 595	11/25/98	European	—	—		
	B12	EP 0 910 584	4/28/99	European	—	—		
	B13	EP 0 923 953	6/23/99	European	—	—		
	B14	EP 0 953 320	11/3/99	European	—	—		
	B15	EP 0 970 711	1/12/00	European	—	—		
	B16	EP 0 982 041	3/1/00	European	—	—		
	B17	EP 1 273 314	1/8/03	European	—	—		
	B18	2001-190687	7/17/01	Japan (Abstract)	—	—	X	
	B19	WO 91/12846	9/5/91	PCT	—	—		
	B20	WO 95/10989	4/27/95	PCT	—	—		
	B21	WO 96/40174	12/19/96	PCT	—	—		
	B22	WO 97/10011	3/20/97	PCT	—	—		
	B23	WO 97/45105	12/4/97	PCT	—	—		
	B24	WO 97/46590	12/11/97	PCT	—	—		
	B25	WO 98/17331	4/30/98	PCT	—	—		
	B26	WO 98/36784	8/27/98	PCT	—	—		
	B27	WO 99/01118	1/14/99	PCT	—	—		
	B28	WO 99/38546	8/5/99	PCT	—	—		
	B29	WO 99/63981	12/16/99	PCT	—	—		
	B30	WO 00/02599	1/20/00	PCT	—	—		
	B31	WO 00/12147	3/9/00	PCT	—	—		
	B32	WO 00/18446	4/6/00	PCT	—	—		
	B33	WO 00/64506	11/2/00	PCT	—	—		
	B34	WO 01/01890	1/11/01	PCT	—	—		
	B35	WO 01/15751	3/8/01	PCT	—	—		
	B36	WO 01/17577	3/15/01	PCT	—	—		
	B37	WO 01/45763	6/28/01	PCT	—	—		
ECC	B38	WO 01/49338	7/12/01	PCT	—	—		

Ecc	B39	WO 01/74414	10/11/01	PCT	—	—		
	B40	WO 02/03890	1/17/02	PCT	—	—		
	B41	WO 02/026162	4/4/02	PCT	—	—		
	B42	WO 02/34311	5/2/02	PCT	—	—		
	B43	WO 02/056790	7/25/02	PCT	—	—		
	B44	WO 03/000308	1/3/03	PCT	—	—		
	B45	WO 03/022323	3/20/03	PCT	—	—		
	B46	WO 03/028780	4/10/03	PCT	—	—		
	B47	WO 03/037223	5/8/03	PCT	—	—		
Ecc	B48	WO 03/039612	5/15/03	PCT	—	—		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Ecc	C1	Anonymous, <i>Cardiologists Draw - Up The Dream Stent</i> , Clinica 710:15 (June 17, 1996), http://www.dialogweb.com/cgi/document?req=1061848202959 , printed 8/25/03 (2 pages).						
	C2	Anonymous, <i>Heparin-coated stents cut complications by 30%</i> , Clinica 732:17 (Nov. 18, 1996), http://www.dialogweb.com/cgi/document?req=1061847871753 , printed 8/25/03 (2 pages).						
	C3	Anonymous, <i>Rolling Therapeutic Agent Loading Device for Therapeutic Agent Delivery or Coated Stent</i> (Abstract 434009), Res. Disclos. pp. 974-975 (June 2000).						
	C4	Anonymous, <i>Stenting continues to dominate cardiology</i> , Clinica 720:22 (Sept. 2, 1996), http://www.dialogweb.com/cgi/document?req=1061848017752 , printed 8/25/03 (2 pages).						
	C5	Aoyagi et al., <i>Preparation of cross-linked aliphatic polyester and application to thermo-responsive material</i> , Journal of Controlled Release 32:87-96 (1994).						
	C6	Barath et al., <i>Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury</i> , JACC 13(2): 252A (Abstract) (Feb. 1989).						
	C7	Barbucci et al., <i>Coating of commercially available materials with a new heparinizable material</i> , J. Biomed. Mater. Res. 25:1259-1274 (Oct. 1991).						
	C8	Chung et al., <i>Inner core segment design for drug delivery control of thermo-responsive polymeric micelles</i> , Journal of Controlled Release 65:93-103 (2000).						
	C9	Dev et al., <i>Kinetics of Drug Delivery to the Arterial Wall Via Polyurethane-Coated Removable Nitinol Stent: Comparative Study of Two Drugs</i> , Catheterization and Cardiovascular Diagnosis 34:272-278 (1995).						
	C10	Dichek et al., <i>Seeding of Intravascular Stents with Genetically Engineered Endothelial Cells</i> , Circ. 80(5):1347-1353 (Nov. 1989).						
	C11	Eigler et al., <i>Local Arterial Wall Drug Delivery from a Polymer Coated Removable Metallic Stent: Kinetics, Distribution, and Bioactivity of Forskolin</i> , JACC, 4A (701-1), Abstract (Feb. 1994).						
	C12	Helmus, <i>Overview of Biomedical Materials</i> , MRS Bulletin, pp. 33-38 (Sept. 1991).						
	C13	Herdeg et al., <i>Antiproliferative Stent Coatings: Taxol and Related Compounds</i> , Semin. Intervent. Cardiol. 3:197-199 (1998).						
	C14	Inoue et al., <i>An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs</i> , Journal of Controlled Release 51:221-229 (1998).						
	C15	Kataoka et al., <i>Block copolymer micelles as vehicles for drug delivery</i> , Journal of Controlled Release 24:119-132 (1993).						
Ecc	C16	Levy et al., <i>Strategies For Treating Arterial Restenosis Using Polymeric Controlled Release Implants</i> , Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).						

ECC	C17	Liu et al., <i>Drug release characteristics of unimolecular polymeric micelles</i> , Journal of Controlled Release 68:167-174 (2000).
	C18	Marconi et al., <i>Covalent bonding of heparin to a vinyl copolymer for biomedical applications</i> , Biomaterials 18(12):885-890 (1997).
	C19	Matsumaru et al., <i>Embolic Materials For Endovascular Treatment of Cerebral Lesions</i> , J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).
	C20	Miyazaki et al., <i>Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice</i> , Chem. Pharm. Bull. 33(6) 2490-2498 (1985).
	C21	Miyazawa et al., <i>Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat</i> , J. Cardiovasc. Pharmacol., pp. 157-162 (1997).
	C22	Nordrehaug et al., <i>A novel biocompatible coating applied to coronary stents</i> , European Heart Journal 14, p. 321 (P1694), Abstr. Suppl. (1993).
	C23	Ohsawa et al., <i>Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty</i> , American Heart Journal 136(6):1081-1087 (Dec. 1998).
	C24	Ozaki et al., <i>New Stent Technologies</i> , Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).
	C25	Pechar et al., <i>Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin</i> , Bioconjugate Chemistry 11(2):131-139 (Mar./Apr. 2000).
	C26	Peng et al., <i>Role of polymers in improving the results of stenting in coronary arteries</i> , Biomaterials 17:685-694 (1996).
	C27	Shigeno, <i>Prevention of Cerebrovascular Spasm By Bosentan, Novel Endothelin Receptor</i> , Chemical Abstract 125:212307 (1996).
	C28	van Beusekom et al., <i>Coronary stent coatings</i> , Coronary Artery Disease 5(7):590-596 (July 1994).
	C29	Wilensky et al., <i>Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries</i> , Trends Cardiovasc. Med. 3(5):163-170 (1993).
ECC	C30	Yokoyama et al., <i>Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor</i> , Journal of Controlled Release 50:79-92 (1998).
EXAMINER		ERMA CAMERON
		DATE CONSIDERED 9/6/05
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		